Skip to content

Monopar Therapeutics

MNPR· NasdaqCore metricsCIK 1645469

Pharmaceutical preparations553 peers

Close
Oct 27, 2026 · -1.02%
Market cap
$485.83M
6.76M shares
Filings
539
$0.00
Q3 2026
-$6.20M
Q3 2026N/M FY25 yoy
-$7.47M
Q3 2026N/M FY25 yoy
—
—
—
-$0.19
Q1 2022N/M FY21 yoy
$52.63M
Q3 2026+35.0% FY25 yoy
$485.83M
—
—
3.8×
—
—

FY2025 figures · derived

Price

$71.8410.77%$8.67past year
Oct 27, 2026 · Official close
Figure
Range
IEX last saleClose of recordAs traded

Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Financials

Revenue

$0.00FY 2025
$0.000FY 2016FY 2017FY 2018FY 2019FY 2024FY 2025
PeriodEndedValueKindSource trail
FY 20252025-12-31$0reported
FY 20242024-12-31$0reported
FY 20192019-12-31$0reported
FY 20182018-12-31$0reported
FY 20172017-12-31$0reported
FY 20162016-12-31$0reported

Capital returns

Dividends and buybacks · FY2024 to FY2025
Fiscal yearDividendsBuybacksTotalPer shareSharesShares · yoyof free cash flow
FY2025—$35.00M$35.00M—6.69M sh+9.5%—
FY2024—$0.00$0.00—6.11M sh−65.0%—

Pharmaceutical preparations

Monopar Therapeutics is the 191st largest of the 554 covered companies the SEC files under this code, by market cap. SIC 2834

Peers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in market cap first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.

Monopar Therapeutics · CIK 1645469 · Engraved from SEC EDGAR